Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025Advanced ScienceOpen Access

Serine/Threonine Kinase 33 as a Novel Target of Bufalin in Treatment of Triple‐Negative Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

SJShilong JiangJLJunyan LiuHLHui Li

Discussion

Loading...

Member takes

Overview

Observational analysis reveals bufalin inhibits cell growth in triple-negative breast cancer by targeting STK33, indicating a novel treatment strategy.

Key Points

  • Bufalin treatment significantly inhibits tumor growth in triple-negative breast cancer by targeting STK33, demonstrating its therapeutic potential.
  • STK33 was found to bind bufalin strongly while being highly expressed in triple-negative breast cancer tissues, suggesting its role as a target.
  • Molecular docking, SPR analysis, and biotin-pulldown experiments confirmed the interaction between bufalin and STK33, a pro-cancer factor in TNBC.
  • This research highlights STK33 as a promising therapeutic target for TNBC, paving the way for future treatment strategies involving bufalin.

Cite This Study

Jiang et al. (2025) studied this question.

synapsesocial.com/papers/68c23caeb210217d64789e8bhttps://doi.org/10.1002/advs.202506253
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiac Glycoside 3β-Bufalin Suppresses Cancer Cell Proliferation by Coupling with Na⁺,K⁺-ATPase and Volume-Regulated Anion Channel Within Membrane Microdomains2026
  2. 2Bufalin Suppresses Colorectal Cancer Liver Metastasis by Inhibiting De Novo Fatty Acid Synthesis via the PI3K/AKT-Mediated SREBP1/FASN Pathway2025 · 3 citations
  3. 3Unraveling the Complexities in TNBC Gene Interaction Networks Towards Better Therapeutics.2025
  4. 4Ursolic Acid Inhibits Triple-Negative Breast Cancer Progression by Modulating the FGFR1/AKT/ERK Pathway: Evidence from Network Pharmacology and Experimental Validation2025
  5. 5Bufalin inhibits hepatocellular carcinoma progression by blocking EGFR-mediated RAS-RAF-MEK-ERK pathway activation2025